Brief: Paion gets positive feedback from Japanese authority PMDA for filing of Remimazolam in Japan
Feb 18 (Reuters) - Paion AG PA8G.DE :
* Receives positive feedback from Japanese authority PMDA
for filing of Remimazolam in 'induction and maintenance of
general anesthesia' in Japan
* PMDA regards clinical and non-clinical data sets as
complete for filing in indication "induction and maintenance of
general anesthesia"
* Important milestone towards commercialization of
remimazolam in Japan and other markets
Source text for Eikon: ID:nEQ1qx9dva
Further company coverage: PA8G.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 39 20;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022